Case report: multiple seizures after a diphenoxylate-atropine overdose in a small child - Wang CH, Song LJ, Yang Y, Qu XP, Lan L, Liu B.
Poisoning is a type of accidental injury and it is considered a major public health problem worldwide. Oral drug poisoning in children is an important cause of accidental injury and even death. It is a common critical emergency in the field of pediatrics. ... (Source: SafetyLit)
Source: SafetyLit - May 4, 2021 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets
For Immediate Release – PEAPACK, NJ, November 16, 2017 - Greenstone LLC, a wholly owned subsidiary of Pfizer Inc., is voluntarily recalling multiple lots of diphenoxylate hydrochloride and atropine sulfate tablets, USP to the consumer level. Greenstone initiated this recall because product from these lots has the pote ntial to be super potent or sub potent. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 25, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
diphenoxylate and atropine (Lomotil)
Title: diphenoxylate and atropine (Lomotil)Category: MedicationsCreated: 7/23/1998 12:00:00 AMLast Editorial Review: 3/1/2019 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - March 1, 2019 Category: Nutrition Source Type: news
Anti-Diarrheal Medication Recalled Over Potency Concerns
Greenstone has recalled several lots of its diphenoxylate hydrochloride and atropine sulfate tablets because they may be super- or subpotent. If the tablets, which are... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 20, 2017 Category: Primary Care Source Type: news
Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets
For Immediate Release – PEAPACK, NJ, November 16, 2017 - Greenstone LLC, a wholly owned subsidiary of Pfizer Inc., is voluntarily recalling multiple lots of diphenoxylate hydrochloride and atropine sulfate tablets, USP to the consumer level. Greenstone initiated this recall because product from these lots has the pote ntial to be super potent or sub potent. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 16, 2017 Category: Food Science Source Type: news
ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets
BAUDETTE, Minn., June 20, 2017 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Diphenoxylate HCl and Atropine Sulfate Tablets, 2.5mg/0.025mg. The annual U.S. market for... Biopharmaceuticals, Generics, Product Launch ANI Pharmaceuticals, Diphenoxylate, Atropine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 20, 2017 Category: Pharmaceuticals Source Type: news
Lomotil (Diphenoxylate and Atropine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 9, 2017 Category: Drugs & Pharmacology Source Type: news
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
